Symbol not found
:OYST 00:00AM GMT
Products, Regulatory
Oyster Point Pharma Submits Phase 2 Clinical Trial Protocol To Evaluate OC-01 Nasal Spray For Neurotrophic Keratitis
Published: 12/01/2020 21:10 GMT
(OYST) - Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate Oc-01 Nasal Spray for Neurotrophic Keratitis (nk).
Oyster Point Pharma Inc - Enrollment of First Patient in Olympia Phase 2 Study in Nk is Planned for First Half of 2021.
Oyster Point Pharma Inc - Remains on Track to File Its NDA for Oc-01 to Treat Signs and Symptoms of Dry Eye Disease in Q4 of 2020.
Oyster Point Pharma Inc - Enrollment of First Patient in Olympia Phase 2 Study in Nk is Planned for First Half of 2021.
Oyster Point Pharma Inc - Remains on Track to File Its NDA for Oc-01 to Treat Signs and Symptoms of Dry Eye Disease in Q4 of 2020.